ATHE

Business Context and Reporting Period

Company: Prana Biotechnology Limited (Note: Metadata listed "Alterity Therapeutics" but filing text confirms "Prana Biotechnology Limited")
Reporting Period: Six months ended December 31, 2007 (Interim)
Filing Date: February 15, 2008
Status: Development stage enterprise focused on therapeutic drugs for brain and eye degeneration (Alzheimer's disease).
Currency: Australian Dollars (A$)

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Increased 7.2% to A$253,876, driven primarily by higher interest income due to increased cash balances from a private placement in October 2007.
• Net Loss: Increased 29.5% to A$10.1 million. The increase is largely due to a non-cash loss on the fair valuation of financial liabilities (warrants) of A$1.86 million and higher operating expenses.
• Operating Expenses:
  • R&D Expenses: Increased 39.2% to A$3.64 million due to drug discovery costs and the Phase IIa clinical trial.
  • Personnel Expenses: Increased 56.3% to A$3.40 million, primarily due to increased equity compensation (options/shares).
  • Audit Fees: Increased 138.2% to A$207,627 due to SEC comment responses.
• Liabilities: Total liabilities more than doubled to A$4.23 million, driven by a revaluation of warrant liabilities from A$321,001 to A$2.18 million.
• Capital Raising: Raised approximately A$8.4 million (gross) via private placement of 29.8 million ordinary shares and associated options.

Outlook, Risks, and Management Commentary

• Clinical Progress: Completed enrollment and dosing for the PBT2 Phase IIa clinical trial for Alzheimer's disease. Results are expected in Q1 2008. The Data Safety Monitoring Board (DSMB) confirmed the trial was safe to continue with no treatment-related serious adverse events.
• Liquidity: Management believes existing cash (A$9.17 million) and anticipated income will support operations for at least 12 months. However, substantial additional funding is required for long-term goals, regulatory approvals, and commercialization.
• Going Concern: The company is a development stage enterprise with an accumulated deficit of A$62.6 million. Directors believe the going concern basis is appropriate due to a history of successful equity fundraising (A$72 million raised to date).
• Risks: Risks include the inherent failure of drug development, the need for significant additional capital, and the volatility of the ADR market price which impacts the valuation of warrant liabilities.
• Unusual Items: A significant non-cash loss of A$1.86 million was recorded due to the fair value revaluation of warrants issued in 2004, which are classified as financial liabilities under A-IFRS because they are exercisable in a foreign currency (USD).

Investor Verification Checklist

• Cash Runway: Verify if the A$9.17 million cash balance is sufficient to fund operations through the anticipated release of Phase IIa results and subsequent regulatory steps.
• Warrant Liability Impact: Confirm the sensitivity of the A$2.18 million warrant liability to fluctuations in the ADR share price and USD/AUD exchange rates.
• Capital Requirements: Assess the specific funding needs for the next 12-24 months and the likelihood of securing additional equity financing given the current market environment.
• Clinical Trial Results: Monitor the Q1 2008 release of PBT2 Phase IIa data, as this is the primary catalyst for future valuation and funding.
• Dilution: Review the terms of the recent private placement and outstanding options (approx. 14.3 million options outstanding) to understand potential future dilution.